Gland Pharma & Neuland Labs Partner for Sterile API Manufacturing

Gland Pharma Limited and Neuland Laboratories Limited have announced a long-term strategic Contract Development and Manufacturing Organization (CDMO) partnership. This collaboration focuses on expanding sterile Active Pharmaceutical Ingredient (API) manufacturing capabilities, particularly for microparticle depot products. Gland Pharma will establish a new, cGMP-compliant sterile manufacturing suite at its Visakhapatnam facility, adding approximately 1400 kg of annual capacity. The partnership aims to leverage Neuland's complex API development expertise with Gland Pharma's sterile manufacturing and regulatory track record to meet growing global demand and enhance supply chain resilience.